Literature DB >> 24284386

Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension.

J E Kontaraki1, M E Marketou2, E A Zacharis2, F I Parthenakis2, P E Vardas2.   

Abstract

Vascular smooth muscle cell (VSMC) phenotypic plasticity has a critical role in the pathophysiology of arterial remodeling in essential hypertension. MicroRNAs are emerging as potential biomarkers and therapeutic targets in cardiovascular disease. We assessed the expression levels of the microRNAs miR-143, miR-145, miR-21, miR-133 and miR-1, which are implicated in VSMC phenotypic modulation, in 60 patients with essential hypertension and 29 healthy individuals. All patients underwent 24-h ambulatory blood pressure (BP) monitoring. MicroRNA levels in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Hypertensive patients showed lower miR-143 (2.20±0.25 versus 4.19±0.57, P<0.001), miR-145 (13.51±1.73 versus 22.38±3.31, P=0.010) and miR-133 (8.15±1.32 versus 37.03±8.18, P<0.001) and higher miR-21 (3.08±0.32 versus 2.06±0.31, P=0.048) and miR-1 (33.94±5.19 versus 12.35±2.13 P=0.006) expression levels compared with controls. In hypertensive patients, we observed correlations of miR-143 (r = -0.380, P=0.003), miR-145 (r=-0.405, P=0.001), miR-21 (r=-0.486, P<0.001) and miR-133 (r=0.479, P<0.001) expression levels with 24-h diastolic BP. Furthermore, we observed correlations of miR-21 (r=-0.291, P=0.024), miR-1 (r=-0.312, P=0.015) and miR-133 (r=0.310, P=0.016) levels with the dipping status. Associations of miR-143 (r=-0.292, P=0.025), miR-145 (r=-0.399, P=0.002), miR-21 (r=-0.343, P=0.008) and miR-133 (r=0.370, P=0.004) levels with 24-h mean pulse pressure were also found. Our data provide important evidence that VSMC-modulating microRNAs are closely related to essential hypertension in humans and they may represent potential therapeutic targets in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284386     DOI: 10.1038/jhh.2013.117

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  37 in total

Review 1.  Ambulatory blood-pressure monitoring.

Authors:  Thomas G Pickering; Daichi Shimbo; Donald Haas
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

Review 2.  Role of microRNAs in cardiac remodeling and heart failure.

Authors:  Veli K Topkara; Douglas L Mann
Journal:  Cardiovasc Drugs Ther       Date:  2011-04       Impact factor: 3.727

Review 3.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 4.  Differential expression of microRNAs in different disease states.

Authors:  Maha Abdellatif
Journal:  Circ Res       Date:  2012-02-17       Impact factor: 17.367

5.  Early cardiac gene transcript levels in peripheral blood mononuclear cells in patients with untreated essential hypertension.

Authors:  Joanna E Kontaraki; Maria E Marketou; Evangelos A Zacharis; Fragiskos I Parthenakis; Panos E Vardas
Journal:  J Hypertens       Date:  2011-04       Impact factor: 4.844

6.  Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: impact of sex and age.

Authors:  Cesare Cuspidi; Stefano Meani; Cristiana Valerio; Carla Sala; Veronica Fusi; Meilikemu Masaidi; Alberto Zanchetti; Giuseppe Mancia
Journal:  Blood Press Monit       Date:  2007-04       Impact factor: 1.444

Review 7.  Pervasive roles of microRNAs in cardiovascular biology.

Authors:  Eric M Small; Eric N Olson
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

Review 8.  MicroRNAs in myocardial infarction.

Authors:  Jan Fiedler; Thomas Thum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 10.  MicroRNAs are involved in end-organ damage during hypertension.

Authors:  Ward A Heggermont; Stephane Heymans
Journal:  Hypertension       Date:  2012-09-17       Impact factor: 10.190

View more
  50 in total

Review 1.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

Review 2.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

Review 3.  Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

Authors:  Roopesh S Gangwar; Sanjay Rajagopalan; Rama Natarajan; Jeffrey A Deiuliis
Journal:  Am J Hypertens       Date:  2018-01-12       Impact factor: 2.689

Review 4.  The emerging role of non-coding RNA in essential hypertension and blood pressure regulation.

Authors:  F Z Marques; S A Booth; F J Charchar
Journal:  J Hum Hypertens       Date:  2014-11-13       Impact factor: 3.012

Review 5.  Wnt signaling, a novel pathway regulating blood pressure? State of the art review.

Authors:  Maen D Abou Ziki; Arya Mani
Journal:  Atherosclerosis       Date:  2017-05-04       Impact factor: 5.162

Review 6.  The Epigenetic Machinery in Vascular Dysfunction and Hypertension.

Authors:  Emile Levy; Schohraya Spahis; Jean-Luc Bigras; Edgard Delvin; Jean-Michel Borys
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

Review 7.  Noncoding RNAs in the Regulatory Network of Hypertension.

Authors:  Gengze Wu; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

8.  An miR-143 promoter variant associated with essential hypertension.

Authors:  Xin Fu; Li Guo; Zheng-Ming Jiang; Luo-Sha Zhao; Ai-Guo Xu
Journal:  Int J Clin Exp Med       Date:  2014-07-15

Review 9.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1.

Authors:  Yong Wang; Liyan Jin
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.